The industry needs "clear guidance regarding royalty payments for innovation ... Unless these companies and [medical] professionals can adopt transparent and trust-based means of interactions, the government won't be satisfied that these just aren't in fact bribes."

Doug Mowen, leader of the medical device advisory process for PricewaterhouseCoopers (New York), discussing the need for a uniform code of ethics in the med-tech sector, "Revising, strengthening what promotes innovation, profits."